Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noac246 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Kazuhiko Mishima und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center Research and Development Funds, Ministry of Health, Labour and Welfare of Japan, AMED.
Abstract (Originalsprache)
Background
The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival.
Methods
An open-label, randomized, phase III trial was conducted in Japan, enrolling immunocompetent patients aged 20–70 years with histologically confirmed, newly diagnosed PCNSL. After administration of HD-MTX, patients were randomly assigned to receive WBRT (30 Gy) ± 10 Gy boost (arm A) or WBRT ± boost with concomitant and maintenance TMZ for 2 years (arm B). The primary endpoint was overall survival (OS).
Results
Between September 29, 2014 and October 15, 2018, 134 patients were enrolled, of whom 122 were randomly assigned and analyzed. At the planned interim analysis, 2-year OS was 86.8% (95% confidence interval [CI]: 72.5–94.0%) in arm A and 71.4% (56.0–82.2%) in arm B. The hazard ratio was 2.18 (95% CI: 0.95–4.98), with the predicted probability of showing the superiority of arm B at the final analysis estimated to be 1.3%. The study was terminated early due to futility. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was measured in 115 tumors, and it was neither prognostic nor predictive of TMZ response.
Conclusions
This study failed to demonstrate the benefit of concomitant and maintenance TMZ in newly diagnosed PCNSL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan.
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
- Radiation Oncology Department, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.
- Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan.
ORCID-Profile: Yoshitaka Narita, Junki Mizusawa, Motoo Nagane, Yoshiki Arakawa, Manabu Natsumeda, Hiroshi Katayama
Förderung
- National Cancer Center Research and Development Funds
- Ministry of Health, Labour and Welfare of Japan
- AMED
- JSPS KAKENHI
- Merck Sharp & Dohme Corp
Zitieren
APA
Mishima, K., Nishikawa, R., Narita, Y., Mizusawa, J., Sumi, M., Koga, T., Sasaki, N., Kinoshita, M., Nagane, M., Arakawa, Y., Yoshimoto, K., Shibahara, I., Shinojima, N., Asano, K., Tsurubuchi, T., Sasaki, H., Asai, A., Sasayama, T., Momii, Y., …, & Fukuda, H. (2023). Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac246
Vancouver
Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Koga T, et al. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac246
BibTeX
@article{Mishima2023,
author = {Mishima, Kazuhiko and Nishikawa, Ryo and Narita, Yoshitaka and Mizusawa, Junki and Sumi, Minako and Koga, Tomoyuki and Sasaki, Nobuyoshi and Kinoshita, Manabu and Nagane, Motoo and Arakawa, Yoshiki and Yoshimoto, Koji and Shibahara, Ichiyo and Shinojima, Naoki and Asano, Kenichiro and Tsurubuchi, Takao and Sasaki, Hikaru and Asai, Akio and Sasayama, Takashi and Momii, Yasutomo and Sasaki, Atsushi and Nakamura, Shigeo and Kojima, Masaru and Tamaru, Jun-Ichi and Tsuchiya, Kazuhiro and Gomyo, Miho and Abe, Kayoko and Natsumeda, Manabu and Yamasaki, Fumiyuki and Katayama, Hiroshi and Fukuda, Haruhiko},
title = {Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noac246}
}
EUVIMED